Highly Efficient Enrichment of N-linked Glycopeptides using a Hydrophilic

Similar documents
Table S1. CRC case Pool Control Pool Name UniProt No. FC b VIP value d Spectral Counts Spectral Counts

Supporting Information. Synthesis of Zwitterionic Polymer Particles via Combined Distillation

High Strength and Hydrophilic Chitosan Microspheres for The Selective Enrichment of N-Glycopeptides

GMI STUDY. COMPARATIVE PROTEOMIC STUDY BETWEEN GMI and STRAUMANN DENTAL IMPLANTS

ESTUDIO GMI. ESTUDIO PROTEÓMICO-COMPARACIÓN IMPLANTES DENTALES

TECHNICAL NOTE. Accurate and fast proteomics analysis of human plasma with PlasmaDive and SpectroDive

Multiple High-Abundant Protein Removal for Proteomics. Dr. Cory Szafranski, Product Manager

Investigation of ovarian cancer associated sialylation changes in N-linked glycopeptides by quantitative proteomics

A Novel Exo-Proteomic Approach to the Study of Traumatic Brain Injury

Profiling the Distribution of N-Glycosylation in Therapeutic Antibodies using the QTRAP 6500 System

Mimi Roy, PhD Senior Director & Site Head Caprion Proteomics US LLC. ISBER, Orlando May 23, 2014

Supporting Information: Protein Corona Analysis of Silver Nanoparticles Exposed to Fish Plasma

Supporting Information

SwissProt/ TrEmbl Acc. No. 1 Description. Found in Other Studies 5. MW (kda) 2 pi 3 Function 4

Proteomic studies in Collagen Induced Arthritis (CIA) rats

Nature Biotechnology: doi: /nbt Supplementary Figure 1

A computational framework for discovery of glycoproteomic biomarkers

Ovarian Cancer-Biomarkers

Supporting information. for. Facile synthesis of enzyme-inorganic hybrid nanoflowers and

Fig. S1. Summary of the altered metabolism pathways in alcoholic fatty liver disease using MetPA analysis (panel A).

A systematic investigation of CID Q-TOF-MS/MS collision energies to allow N- and O-glycopeptide identification by LC-MS/MS

Differential effects of insulin deprivation and systemic insulin treatment on plasma protein synthesis in type 1 diabetic people

Introduction. Methods RESEARCH FUND FOR THE CONTROL OF INFECTIOUS DISEASES. TCW Poon *, HLY Chan, HWC Leung, A Lo, RHY Lau, AY Hui, JJY Sung

Proteomic Approach for Identification of IgA Nephropathy-Related Biomarkers in Urine

Electronic Supplementary Information

Detailed Analysis of Polyclonal IgG with Emphasis on Sialylation and Sub-Classes After Fractionation on a Sialic-Acid Binding Lectin

Nature Biotechnology: doi: /nbt Supplementary Figure 1. RNAseq expression profiling of selected glycosyltransferase genes in CHO.

Electronic Supplementary Material

Turbidos. Design Verification. Contents

Naoya Takahashi, Keiya Hirota and Yoshitaka Saga* Supplementary material

PPI. The Clinical Potential of the Human Plasma Proteome. The Plasma Proteome Institute

SUPPLEMENTAL TABLE I. Identified Proteins in Bovine Testicular Hyaluronidase Type I-S via LC-MS/MS

Isomeric Separation of Permethylated Glycans by Porous Graphitic Carbon (PGC)-LC-MS/MS at High- Temperatures

Electronic Supplementary Information (ESI) A unique dansyl-based chromogenic chemosensor for rapid and ultrasensitive hydrazine detection

Supplementary Materials for

Two independent proteomic approaches provide a comprehensive analysis of the synovial fluid proteome response to Autologous Chondrocyte Implantation

Application Note # ET-17 / MT-99 Characterization of the N-glycosylation Pattern of Antibodies by ESI - and MALDI mass spectrometry

Electronic Supplementary Information

Supplementary Information

Human plasma protein N-glycosylation

Surface-Enhanced Raman Scattering Active Gold Nanoparticles. with Enzyme-Mimicking Activities for Measuring Glucose and

Study of On-Resin Convergent Synthesis of N-Linked. Glycopeptides Containing a Large High Mannose N- Linked Oligosaccharide

Supporting Information. Dynamic Proteome Alteration and Functional Modulation of. Human Saliva Induced by Dietary Chemosensory Stimuli

Current Glycoprotein Analysis. Glycan Characterization: Oligosaccharides. Glycan Analysis: Sample Preparation. Glycan Analysis: Chromatography

on Non-Consensus Protein Motifs Analytical & Formulation Sciences, Amgen. Seattle, WA

Dr Cédric DELPORTE Prof. Ass. Dr Pierre VAN ANTWERPEN

Chapter 13. Plasma Proteins and Enzymes. Lecturer: Dr Abeer Shnoudeh. Clinical Chemistry William Marshall

Liver cancer and normal cell lines

Supporting Information

Increasing Molecular Coverage in Complex Biological and Environmental Samples by Using IMS-MS

Extended Mass Range Triple Quadrupole for Routine Analysis of High Mass-to-charge Peptide Ions

Supporting Information for MassyTools-assisted data analysis of total serum N-glycome changes associated with pregnancy

Linear Growth of Glycomics

Coordination-responsive Selenium-containing Polymer Micelles for. Supporting information

Supporting information

Plasma proteomic analysis of systemic lupus erythematosus patients using liquid chromatography/tandem mass spectrometry with label-free quantification

Supplementary Information

Modification of sialic acids on solid-phase: accurate characterization of. protein sialylation

Protein Identification and Phosphorylation Site Determination by de novo sequencing using PepFrag TM MALDI-Sequencing kit

L-Carnosine-Derived Fmoc-Tripeptides Forming ph- Sensitive and Proteolytically Stable Supramolecular

ROS scavenging Mn 3 O 4 nanozymes for in vivo anti-inflammation

Supporting Information. Self-assembling glutamate functionalized cyclodextrin molecular tube for specific enrichment of. N-linked glycopeptides

Structural Elucidation of N-glycans Originating From Ovarian Cancer Cells Using High-Vacuum MALDI Mass Spectrometry

Electron transfer dissociation (ETD)

Protein glycosylation is one of the most common posttranslational

An#body structure & func#on

Figure S7: ATR FTIR spectra of enantiomeric UP-PLA-UPy and sc-upy-pla-upy. Figure S9: SEM microphotographs sc-upy-pla-oh in 1,4-dioxane and chloroform

Flow-Through Electron Capture Dissociation in a novel Branched RF Ion Trap

Separation of Main Proteins in Plasma and Serum

I) Choose the best answer: 1- All of the following amino acids are neutral except: a) glycine. b) threonine. c) lysine. d) proline. e) leucine.

Supporting Information. as the nitro source

High-sensitivity Orbitrap mass analysis of intact macromolecular assemblies. R. J. Rose, E. Damoc, E. Denisov, A. Makarov, A. J. R.

Plasma proteins Quantitatively, proteins are the most important part of the soluble components of the blood plasma.

C-reactive protein. An ED perspective Greg Stevens May 2010

Supporting Information. Chemoenzymatic Synthesis of Galectin Binding. Glycopolymers

1. Structure, classification, functions, properties of proteins

Laboratory diagnosis of plasma proteins and plasma enzymes

Chapter 2. Chemical Composition of the Body

Research Article Urine Glycoprotein Profile Reveals Novel Markers for Chronic Kidney Disease

5 Identification of Binding Partners of the Annexin A2 / P11 Complex by Chemical Cross-Linking

Ch. 45 Blood Plasma proteins, Coagulation and Fibrinolysis Student Learning Outcomes: Describe basic components of plasma

BlotGlyco Glycan purification and labeling kit

Fabrication of Bio-based Polyelectrolyte Capsules and Their Application for Glucose-Triggered Insulin Delivery

Separation of Plasma and Serum and Their Proteins from Whole Blood

ph Switchable and Fluorescent Ratiometric Squarylium Indocyanine Dyes as Extremely Alkaline Sensors

Supporting Information. Zinc hydroxide nanostrands: unique precursor for ZIF-8. thin membranes toward highly size-sieving gas separation

TECHNICAL BULLETIN. R 2 GlcNAcβ1 4GlcNAcβ1 Asn

A pillar[2]arene[3]hydroquinone which can self-assemble to a molecular zipper in the solid state

Thank you for joining us! Our session will begin shortly Waters Corporation 1

Supplementary Material (ESI) for Chemical Communications This journal is (c) The Royal Society of Chemistry 2011

Proteomic analysis of human plasma in chronic rheumatic mitral stenosis reveals proteins involved in the complement and coagulation cascade

Chukvelutins A-C, 16-norphragmalin limonoids with unprecedented skeletons from Chukrasia tabularis var. velutina

Disaccharides. Compound dehydration synthesis puts sugars together Hydrolysis (hydro-water, lysisbreakdown)

Immunoassay. Product Portfolio. Part of the IDS group

Supporting Information

LC MS/MS Quantitation of Esophagus Disease Blood Serum Glycoproteins by Enrichment with Hydrazide Chemistry and Lectin Affinity Chromatography

Facile Cu(II) mediated conjugation of thioesters and thioacids to peptides and proteins under mild conditions

Supporting Information Parsimonious Charge Deconvolution for Native Mass Spectrometry

Glycosylation analyses of recombinant proteins by LC-ESI mass spectrometry

Quantitative Analysis of Acrylamide Labeled Serum Proteins by LC-MS/MS

Transcription:

Electronic Supplementary Material (ESI) for Analyst. This journal is The Royal Society of Chemistry 2017 Supporting Information Highly Efficient Enrichment of N-linked Glycopeptides using a Hydrophilic Covalent-Organic Framework Yu-Fang Ma, Fang Yuan, Xiao-Hui Zhang, Ying-Lin Zhou* and Xin-Xiang Zhang* Beijing National Laboratory for Molecular Sciences (BNLMS), MOE Key Laboratory of Bioorganic Chemistry and Molecular Engineering, College of Chemistry, Peking University, Beijing 100871, China. Corresponding Authors E-mail addresses: zhouyl@pku.edu.cn, zxx@pku.edu.cn; Fax: +86-10-62754112; Tel: +86-10-62754112. S1

OH HMTA,TFA 3M HCl OHC OH CHO HO OH 100 C 2.5 h, under nitrogen 100 C 1 h, under nitrogen HO CHO OH dried phloroglucinol 1, 3, 5-triformylphloroglucinol Scheme S1 Schematic representation of the synthesis of 1, 3, 5-triformylphloroglucinol (Tp). OHC HO OH CHO CHO OH NH 2 NH 2 Schiff base reaction N HO N OH OH N NH O HN O O N H Tp Pa-1 Enlo form Keto form Scheme S2 Schematic representation of the synthesis of TpPa-1. Fig. S1 1 H NMR spectrum of synthesized Tp. S2

Fig. S2 13 C NMR spectrum of synthesized Tp. Fig. S3 FT-IR spectra of (A) synthesized TpPa-1, (B) Pa-1 and (C) synthesized Tp. S3

Fig. S4 XRD patterns of (A) synthesized TpPa-1 and (B) simulated TpPa-1. Fig. S5 SEM images of synthesized TpPa-1. S4

Fig. S6 MALDI-TOF MS spectra of human IgG tryptic digests after TpPa-1 enrichment with different elution buffers (A) ACN/H 2 O/TFA (79.9/20/0.1, v/v/v), (B) ACN/H 2 O/TFA (84.9/15/0.1, v/v/v) and (C) ACN/H 2 O/TFA (89.9/10/0.1, v/v/v). N-linked glycopeptides are marked with solid red circles. S5

Fig. S7 MALDI-TOF MS spectra of human IgG tryptic digests after enrichment with TpPa-1 (A) for the third time, (B) for the sixth time and (C) for the tenth time. N-linked glycopeptides are marked with solid red circles. S6

Table S1 Observed molecular masses of N-linked glycopeptides and proposed glycan composition of human IgG tryptic digests enriched by TpPa-1. Hex, HexNAc, Fuc and NeuAc are the abbreviations of hexose, N- acetylhexosamine, fucose and N-acetylneuraminic acid, respectively. N# denotes the N-linked glycosylation sites. Peak number Observed m/z Glycan composite Peptide sequence I1 2398.7 [Hex]3[HexNAc]3[Fuc]1 EEQFN#STFR I2 2430.7 [Hex]3[HexNAc]3[Fuc]1 EEQYN#STYR I3 2456.0 [Hex]3[HexNAc]4 EEQFN#STFR I4 2487.9 [Hex]3[HexNAc]4 EEQYN#STYR I5 2560.9 [Hex]4[HexNAc]3[Fuc]1 EEQFN#STFR I6 2592.9 [Hex]4[HexNAc]3[Fuc]1 EEQYN#STYR I7 2601.9 [Hex]3[HexNAc]4[Fuc]1 EEQFN#STFR I8 2617.9 [Hex]4[HexNAc]4 EEQFN#STFR I9 2633.9 [Hex]3[HexNAc]4[Fuc]1 EEQYN#STYR I10 2650.0 [Hex]4[HexNAc]4 EEQYN#STYR I11 2658.9 [Hex]3[HexNAc]5 EEQFN#STFR I12 2690.9 [Hex]3[HexNAc]5 EEQYN#STYR I13 2764.1 [Hex]4[HexNAc]4[Fuc]1 EEQFN#STFR I14 2780.0 [Hex]5[HexNAc]4 EEQFN#STFR I15 2796.1 [Hex]4[HexNAc]4[Fuc]1 EEQYN#STYR I16 2804.8 [Hex]3[HexNAc]5[Fuc]1 EEQFN#STYR I17 2812.0 [Hex]5[HexNAc]4 EEQYN#STFR I18 2820.9 [Hex]4[HexNAc]5 EEQFN#STFR I19 2836.9 [Hex]3[HexNAc]5[Fuc]1 EEQYN#STYR I20 2853.0 [Hex]4[HexNAc]5 EEQYN#STYR I21 2909.8 [Hex]4[HexNAc]4 [NeuAc]1 EEQFN#STFR I22 2926.0 [Hex]5[HexNAc]4[Fuc]1 EEQFN#STFR I23 2958.0 [Hex]5[HexNAc]4[Fuc]1 EEQYN#STYR I24 2967.0 [Hex]4[Hex7NAc]5[Fuc]1 EEQFN#STFR I25 2983.1 [Hex]5[HexNAc]5 EEQFN#STFR I26 2999.0 [Hex]4[HexNAc]5[Fuc]1 EEQYN#STYR I27 3015.1 [Hex]5[HexNAc]5 EEQYN#STYR I28 3055.8 [Hex]4[HexNAc]4[Fuc]1[NeuAc]1 EEQFN#STFR S7

I29 3129.7 [Hex]5[HexNAc]5[Fuc]1 EEQFN#STFR I30 3160.9 [Hex]5[HexNAc]5[Fuc]1 EEQYN#STYR I31 3218.0 [Hex]5[HexNAc]4[Fuc]1[NeuAc]1 EEQFN#STFR I32 3248.9 [Hex]5[HexNAc]4[Fuc]1[NeuAc]1 EEQYN#STYR Table S2 Observed molecular masses of N-linked glycopeptides and proposed glycan composition of HRP tryptic digests enriched by TpPa-1. Hex, HexNAc, Fuc and Xyl are the abbreviations of hexose, N-acetylhexosamine, fucose and xylose, respectively. N# denotes the N-linked glycosylation sites. Peak Observed number m/z Glycan composite Peptide sequence H1 1842.5 [Hex]3[HexNAc]2[Fuc]1[Xyl]1 NVGLN#R H2 2068.6 [Hex]3[HexNAc]2[Fuc]1[Xyl]1 PNVSN#IVR H3 2541.0 [Hex]3[HexNAc]2[Fuc]1[Xyl]1 SSPN#ATDTIPLVR H4 2590.7 [Hex]3[HexNAc]2[Fuc]1[Xyl]1 PTLN#TTYLQTLR H5 2611.7 [Hex]3[HexNAc]2[Xyl]1 MGN#ITPLTGTQGQIR H6 2802.7 [Hex]2[HexNAc]2 MGN#ITPLTGTQGQIRLNCR H7 3073.8 [HexNAc]1[Fuc]1 LHFHDCFVNGCDASILLDN#TTSFR H8 3145.8 [Hex]3[HexNAc]2[Fuc]1[Xyl]1 GLCPLNGN#LSALVDFDLR H9 3188.8 [HexNAc]1[Fuc]1 LHFHDCFVNGCDASILLDN#TTSFR H10 3206.2 [Hex]3[HexNAc]2[Xyl]1 SFAN#STQTFFNAFVEAMDR H11 3320.8 [Hex]3[HexNAc]2[Fuc]1[Xyl]1 QLTPTFYDNSCPN#VSNIVR H12 3352.8 [Hex]3[HexNAc]2[Fuc]1[Xyl]1 SFAN#STQTFFNAFVEAMDR H13 3369.0 [Hex]3[HexNAc]2[Fuc]1[Xyl]1 SFAN#STQTFFNAFNEAM*DR H14 3377.8 [Hex]2[HexNAc]2[Fuc]1 GLIQSDQELFSSPN#ATDTIPLVR H15 3525.5 [Hex]3[HexNAc]2[Xyl]1 GLIQSDQELFSSPN#ATDTIPLVR H16 3670.9 [Hex]3[HexNAc]2[Fuc]1[Xyl]1 GLIQSDQELFSSPN#ATDTIPLVR H17 3813.2 [Hex]2[HexNAc]2 LHFHDCFVNGCDASILLDN#TTSFR TEK H18 3894.7 [Hex]3[HexNAc]2[Fuc]1[Xyl]1 LHFHDCFVNGCDASILLDN#TTSFR H19 4719.2 [Hex]3[HexNAc]2[Fuc]1 LYN#FSNTGLPDPTLN#TTYLQTLR [Hex]3[HexNAc]2[Fuc]1 H20 4837.2 [Hex]3[HexNAc]2[Fuc]1[Xyl]1 [Hex]3[HexNAc]2[Xyl]1 LYN#FSNTGLPDPTLN#TTYLQTLR S8

H21 4851.2 [Hex]3[HexNAc]2[Fuc]1[Xyl]1 [Hex]3[HexNAc]2[Fuc]1 H22 4982.9 [Hex]3[HexNAc]2[Fuc]1[Xyl]1 [Hex]3[HexNAc]2[Fuc]1[Xyl]1 LYN#FSNTGLPDPTLN#TTYLQTLR LYN#FSNTGLPDPTLN#TTYLQTLR Table S3 Observed N-linked glycopeptides of human serum tryptic digests enriched by TpPa-1. OS=Organism Name, GN=Gene Name, PE=Protein Existence, SV=Sequence Version. N# denotes the N-linked glycosylation sites. Protein Accession Number FETUA_HUMAN FETUA_HUMAN FETUA_HUMAN IGHG1_HUMAN A2MG_HUMAN A2MG_HUMAN A2MG_HUMAN A1AT_HUMAN Protein Description Alpha-2-HS-glycoprotein OS=Homo sapiens GN=AHSG Alpha-2-HS-glycoprotein OS=Homo sapiens GN=AHSG Alpha-2-HS-glycoprotein OS=Homo sapiens GN=AHSG Ig gamma-1 chain C region OS=Homo sapiens GN=IGHG1 Alpha-2-macroglobulin OS=Homo sapiens GN=A2M Alpha-2-macroglobulin OS=Homo sapiens GN=A2M Alpha-2-macroglobulin OS=Homo sapiens GN=A2M Alpha-1-antitrypsin OS=Homo sapiens GN=SERPINA1 PE=1 Peptide Sequence VCQDCPLLAPLN#DTR KVCQDCPLLAPLN#DTR AALAAFNAQNN#GSNFQLEEISR EEQYN#STYR VSN#QTLSLFFTVLQDVPVR GCVLLSYLN#ETVTVSASLESVR SLGNVN#FTVSAEALESQELCGTEVPSVPEH GR YLGN#ATAIFFLPDEGK S9

SV=3 A1AT_HUMAN Alpha-1-antitrypsin OS=Homo ADTHDEILEGLNFN#LTEIPEAQIHEGFQELL sapiens GN=SERPINA1 PE=1 R SV=3 CO3_HUMAN Complement C3 OS=Homo TVLTPATNHMGN#VTFTIPANR sapiens GN=C3 HEMO_HUMAN Hemopexin OS=Homo sapiens SWPAVGN#CSSALR GN=HPX HEMO_HUMAN Hemopexin OS=Homo sapiens ALPQPQN#VTSLLGCTH GN=HPX HEMO_HUMAN Hemopexin OS=Homo sapiens N#GTGHGN#STHHGPEYMR GN=HPX IGHG4_HUMAN Ig gamma-4 chain C region EEQFN#STYR OS=Homo sapiens GN=IGHG4 IGHG2_HUMAN Ig gamma-2 chain C region EEQFN#STFR OS=Homo sapiens GN=IGHG2 IGHG3_HUMAN Ig gamma-3 chain C region OS=Homo sapiens GN=IGHG3 EEQYN#STFR CERU_HUMAN Ceruloplasmin OS=Homo EHEGAIYPDN#TTDFQR sapiens GN=CP CERU_HUMAN Ceruloplasmin OS=Homo ELHHLQEQN#VSNAFLDK sapiens GN=CP CERU_HUMAN Ceruloplasmin OS=Homo EN#LTAPGSDSAVFFEQGTTR sapiens GN=CP CERU_HUMAN Ceruloplasmin OS=Homo ELHHLQEQN#VSNAFLDKGEFYIGSK sapiens GN=CP CLUS_HUMAN Clusterin OS=Homo sapiens HN#STGCLR GN=CLU CLUS_HUMAN Clusterin OS=Homo sapiens EDALN#ETR GN=CLU CLUS_HUMAN Clusterin OS=Homo sapiens KEDALN#ETR S10

GN=CLU CLUS_HUMAN Clusterin OS=Homo sapiens GN=CLU CLUS_HUMAN Clusterin OS=Homo sapiens GN=CLU IGHA2_HUMAN Ig alpha-2 chain C region OS=Homo sapiens GN=IGHA2 PE=1 SV=3 IGHA2_HUMAN Ig alpha-2 chain C region OS=Homo sapiens GN=IGHA2 PE=1 SV=3 IGHA1_HUMAN Ig alpha-1 chain C region OS=Homo sapiens GN=IGHA1 IGHA1_HUMAN Ig alpha-1 chain C region OS=Homo sapiens GN=IGHA1 A1AG1_HUMAN Alpha-1-acid glycoprotein 1 OS=Homo sapiens GN=ORM1 A1AG1_HUMAN Alpha-1-acid glycoprotein 1 OS=Homo sapiens GN=ORM1 ANT3_HUMAN Antithrombin-III OS=Homo sapiens GN=SERPINC1 PE=1 SV=1 ANT3_HUMAN Antithrombin-III OS=Homo sapiens GN=SERPINC1 PE=1 SV=1 ANT3_HUMAN Antithrombin-III OS=Homo sapiens GN=SERPINC1 PE=1 SV=1 ANT3_HUMAN Antithrombin-III OS=Homo sapiens GN=SERPINC1 PE=1 KKEDALN#ETR LAN#LTQGEDQYYLR TPLTAN#ITK LSLHRPALEDLLLGSEAN#LTCTLTGLR LAGKPTHVN#VSVVMAEVDGTCY LSLHRPALEDLLLGSEAN#LTCTLTGLR EN#GTISR QDQCIYN#TTYLNVQR WVSN#KTEGR LGACN#DTLQQLMEVFK SLTFN#ETYQDISELVYGAK LGACN#DTLQQLMEVFKFDTISEK S11

SV=1 ZA2G_HUMAN Zinc-alpha-2-glycoprotein OS=Homo sapiens GN=AZGP1 HPT_HUMAN Haptoglobin OS=Homo sapiens GN=HP HPT_HUMAN Haptoglobin OS=Homo sapiens GN=HP HPT_HUMAN Haptoglobin OS=Homo sapiens GN=HP APOB_HUMAN Apolipoprotein B-100 OS=Homo sapiens GN=APOB APOB_HUMAN Apolipoprotein B-100 OS=Homo sapiens GN=APOB APOB_HUMAN Apolipoprotein B-100 OS=Homo sapiens GN=APOB APOB_HUMAN Apolipoprotein B-100 OS=Homo sapiens GN=APOB APOB_HUMAN Apolipoprotein B-100 OS=Homo sapiens GN=APOB APOB_HUMAN Apolipoprotein B-100 OS=Homo sapiens GN=APOB IGHM_HUMAN Ig mu chain C region OS=Homo sapiens GN=IGHM PE=1 SV=3 IGHM_HUMAN Ig mu chain C region OS=Homo sapiens GN=IGHM PE=1 SV=3 IGHM_HUMAN Ig mu chain C region OS=Homo sapiens GN=IGHM PE=1 SV=3 DIVEYYN#DSN#GSHVLQGR NLFLN#HSEN#ATAK VVLHPN#YSQVDIGLIK MVSHHN#LTTGATLINEQWLLTTAK YDFN#SSMLYSTAK FVEGSHN#STVSLTTK FN#SSYLQGTNQITGR VNQNLVYESGSLN#FSK FEVDSPVYN#ATWSASLK QVFPGLNYCTSGAYSN#ASSTDSASYYPLTG DTR N#NSDISSTR YKN#NSDISSTR GLTFQQN#ASSMCVPDQDTAIR S12

IGHM_HUMAN Ig mu chain C region OS=Homo sapiens GN=IGHM PE=1 SV=3 VTNC_HUMAN Vitronectin OS=Homo sapiens GN=VTN CO4A_HUMAN Complement C4-A OS=Homo sapiens GN=C4A CO4A_HUMAN Complement C4-A OS=Homo sapiens GN=C4A APOH_HUMAN Beta-2-glycoprotein 1 OS=Homo sapiens GN=APOH PE=1 SV=3 APOH_HUMAN Beta-2-glycoprotein 1 OS=Homo sapiens GN=APOH PE=1 SV=3 AACT_HUMAN Alpha-1-antichymotrypsin OS=Homo sapiens GN=SERPINA3 AACT_HUMAN Alpha-1-antichymotrypsin OS=Homo sapiens GN=SERPINA3 HRG_HUMAN Histidine-rich glycoprotein OS=Homo sapiens GN=HRG CFAH_HUMAN Complement factor H OS=Homo sapiens GN=CFH PE=1 SV=4 CFAH_HUMAN Complement factor H OS=Homo sapiens GN=CFH PE=1 SV=4 CFAH_HUMAN Complement factor H OS=Homo sapiens GN=CFH PE=1 SV=4 A1AG2_HUMAN Alpha-1-acid glycoprotein 2 OS=Homo sapiens GN=ORM2 THTN#ISESHPN#ATFSAVGEASICEDDWNS GER NN#ATVHEQVGGPSLTSDLQAQSK GLN#VTLSSTGR FSDGLESN#SSTQFEVK LGN#WSAMPSCK VYKPSAGN#NSLYR YTGN#ASALFILPDQDK FN#LTETSEAEIHQSFQHLLR VIDFN#CTTSSVSSALANTK MDGASN#VTCINSR ISEEN#ETTCYMGK IPCSQPPQIEHGTIN#SSR EN#GTVSR S13

A1AG2_HUMAN Alpha-1-acid glycoprotein 2 OS=Homo sapiens GN=ORM2 CBG_HUMAN Corticosteroid-binding globulin OS=Homo sapiens GN=SERPINA6 KAIN_HUMAN Kallistatin OS=Homo sapiens GN=SERPINA4 PE=1 SV=3 KAIN_HUMAN Kallistatin OS=Homo sapiens GN=SERPINA4 PE=1 SV=3 KNG1_HUMAN Kininogen-1 OS=Homo sapiens GN=KNG1 KNG1_HUMAN Kininogen-1 OS=Homo sapiens GN=KNG1 C4BPA_HUMAN C4b-binding protein alpha chain OS=Homo sapiens GN=C4BPA APOD_HUMAN Apolipoprotein D OS=Homo sapiens GN=APOD APOD_HUMAN Apolipoprotein D OS=Homo sapiens GN=APOD FINC_HUMAN Fibronectin OS=Homo sapiens GN=FN1 PE=1 SV=3 FINC_HUMAN Fibronectin OS=Homo sapiens GN=FN1 PE=1 SV=3 ITIH4_HUMAN Inter-alpha-trypsin inhibitor heavy chain H4 OS=Homo sapiens GN=ITIH4 PE=1 SV=4 LG3BP_HUMAN Galectin-3-binding protein OS=Homo sapiens GN=LGALS3BP LG3BP_HUMAN Galectin-3-binding protein OS=Homo sapiens GN=LGALS3BP QNQCFYN#SSYLNVQR AQLLQGLGFN#LTER DFYVDEN#TTVR SQILEGLGFN#LTELSESDVHR ITYSIVQTN#CSK LNAENN#ATFYFK LSVDKDQYVEPEN#VTIQCDSGYGVVGPQS ITCSGNR ADGTVNQIEGEATPVN#LTEPAK ADGTVNQIEGEATPVN#LTEPAKLEVK DQCIVDDITYNVN#DTFHK LDAPTNLQFVN#ETDSTVLVR LPTQN#ITFQTESSVAEQEAEFQSPK DAGVVCTN#ETR AAIPSALDTN#SSK S14

LG3BP_HUMAN Galectin-3-binding protein OS=Homo sapiens GN=LGALS3BP LG3BP_HUMAN Galectin-3-binding protein OS=Homo sapiens GN=LGALS3BP BTD_HUMAN Biotinidase OS=Homo sapiens GN=BTD BTD_HUMAN Biotinidase OS=Homo sapiens GN=BTD AFAM_HUMAN Afamin OS=Homo sapiens GN=AFM AFAM_HUMAN Afamin OS=Homo sapiens GN=AFM ATRN_HUMAN Attractin OS=Homo sapiens GN=ATRN ATRN_HUMAN Attractin OS=Homo sapiens GN=ATRN ATRN_HUMAN Attractin OS=Homo sapiens GN=ATRN KLKB1_HUMAN Plasma kallikrein OS=Homo sapiens GN=KLKB1 KLKB1_HUMAN Plasma kallikrein OS=Homo sapiens GN=KLKB1 KLKB1_HUMAN Plasma kallikrein OS=Homo sapiens GN=KLKB1 IGJ_HUMAN Immunoglobulin J chain OS=Homo sapiens GN=IGJ PE=1 SV=4 FHR1_HUMAN Complement factor H-related protein 1 OS=Homo sapiens GN=CFHR1 C4BPB_HUMAN C4b-binding protein beta chain OS=Homo sapiens GN=C4BPB ALGFEN#ATQALGR GLN#LTEDTYKPR FN#DTEVLQR NPVGLIGAEN#ATGETDPSHSK DIENFN#STQK YAEDKFN#ETTEK GICN#SSDVR IDSTGN#VTNELR N#HSCSEGQISIFR GVNFN#VSK IYSGILN#LSDITK IYPGVDFGGEELN#VTFVK EN#ISDPTSPLR LQNNENN#ISCVER EWDN#TTTECR S15

C4BPB_HUMAN C4b-binding protein beta chain OS=Homo sapiens GN=C4BPB MUCB_HUMAN Ig mu heavy chain disease protein OS=Homo sapiens CFAI_HUMAN Complement factor I OS=Homo sapiens GN=CFI CFAI_HUMAN Complement factor I OS=Homo sapiens GN=CFI PON1_HUMAN Serum paraoxonase/arylesterase 1 OS=Homo sapiens GN=PON1 PON1_HUMAN Serum paraoxonase/arylesterase 1 OS=Homo sapiens GN=PON1 PEDF_HUMAN Pigment epithelium-derived factor OS=Homo sapiens GN=SERPINF1 PE=1 SV=3 CO9_HUMAN Complement component C9 OS=Homo sapiens GN=C9 PE=1 SV=2 LUM_HUMAN Lumican OS=Homo sapiens GN=LUM LUM_HUMAN Lumican OS=Homo sapiens GN=LUM LUM_HUMAN Lumican OS=Homo sapiens GN=LUM CPN2_HUMAN Carboxypeptidase N subunit 2 OS=Homo sapiens GN=CPN2 CPN2_HUMAN Carboxypeptidase N subunit 2 OS=Homo sapiens GN=CPN2 LGHCPDPVLVNGEFSSSGPVN#VSDK THTN#ISESHPN#ATFSAVGEASICEDDWDS GER FLNN#GTCTAEGK LSDLSIN#STECLHVHCR HAN#WTLTPLK VTQVYAEN#GTVLQGSTVASVYK VTQN#LTLIEESLTSEFIHDIDR AVN#ITSENLIDDVVSLIR LHINHNN#LTESVGPLPK LGSFEGLVN#LTFIHLQHNR AFEN#VTDLQWLILDHNLLENSK AFGSNPN#LTK LYLGSNN#LTALHPALFQN#LSK S16

IBP3_HUMAN Insulin-like growth factorbinding protein 3 OS=Homo sapiens GN=IGFBP3 THRB_HUMAN Prothrombin OS=Homo sapiens GN=F2 THRB_HUMAN Prothrombin OS=Homo sapiens GN=F2 THRB_HUMAN Prothrombin OS=Homo sapiens GN=F2 C1QA_HUMAN Complement C1q subcomponent subunit A OS=Homo sapiens GN=C1QA TSP1_HUMAN Thrombospondin-1 OS=Homo sapiens GN=THBS1 HEP2_HUMAN Heparin cofactor 2 OS=Homo sapiens GN=SERPIND1 PE=1 SV=3 SEPP1_HUMAN Selenoprotein P OS=Homo sapiens GN=SEPP1 PE=1 SV=3 CHP1_HUMAN Calcium-binding protein p22 OS=Homo sapiens GN=CHP PE=1 SV=3 IGHD_HUMAN Ig delta chain C region OS=Homo sapiens GN=IGHD CHLE_HUMAN Cholinesterase OS=Homo sapiens GN=BCHE PHLD_HUMAN Phosphatidylinositol-glycanspecific phospholipase D OS=Homo sapiens GN=GPLD1 PE=1 SV=3 GLCVN#ASAVSR GHVN#ITR N#FTENDLLVR YPHKPEIN#STTHPGADLQENFCR RNPPMGGNVVIFDTVITNQEEPYQN#HSG R VVN#STTGPGEHLR DFVN#ASSK EGYSN#ISYIVVNHQGISSR GEN#GTLSR TLLN#ASR DN#NSIITR N#LTTSLTESVDR S17

PGRP2_HUMAN N-acetylmuramoyl-L-alanine GFGVAIVGN#YTAALPTEAALR amidase OS=Homo sapiens GN=PGLYRP2 PGRP2_HUMAN N-acetylmuramoyl-L-alanine LEPVHLQLQCMSQEQLAQVAAN#ATK amidase OS=Homo sapiens GN=PGLYRP2 APOM_HUMAN Apolipoprotein M OS=Homo TELFSSSCPGGIMLN#ETGQGYQR sapiens GN=APOM LPAL2_HUMAN Apolipoprotein(a)-like protein 2 OS=Homo sapiens GN=LPAL2 PE=2 SV=1 WEYCN#LTR THBG_HUMAN Thyroxine-binding globulin TLYETEVFSTDFSN#ISAAK OS=Homo sapiens GN=SERPINA7 CO6_HUMAN Complement component C6 VLN#FTTK OS=Homo sapiens GN=C6 PE=1 SV=3 WDTC1_HUMAN VN#ITR LAMB2_HUMAN Laminin subunit beta-2 VN#LTR OS=Homo sapiens GN=LAMB2 PLTP_HUMAN Phospholipid transfer protein VSN#VSCQASVSR OS=Homo sapiens GN=PLTP FA10_HUMAN Coagulation factor X OS=Homo GDNN#LTR sapiens GN=F10 LYAM1_HUMAN L-selectin OS=Homo sapiens GN=SELL DN#YTDLVAIQNK C1S_HUMAN Complement C1s NCGVN#CSGDVFTALIGEIASPNYPKPYPEN subcomponent OS=Homo SR sapiens GN=C1S LYVE1_HUMAN Lymphatic vessel endothelial ANQQLN#FTEAK hyaluronic acid receptor 1 OS=Homo sapiens GN=LYVE1 S18

S19